Caplin Point Lab (CAPLIPOINT)

FairStock Score: 83/100 — HIGH CONVICTION

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Zero debt with ROE 23.30% and ROCE 25.85%; strong balance sheet and capital efficiency.
• Promoter holding at 70.57% aligns management with minority shareholders.
• Profit growth of 19.09% is outpacing sales growth of 10.66%, indicating margin expansion.
• Piotroski F-Score of 8/9 and Altman Z-Score of 4.62 point to solid financial health.
• Negative EV/EBITDA of -30.23 suggests substantial net cash or investments on the balance sheet.

Concerns

• Valuation is rich: P/E 21.06, P/B 5.10, price far above Graham Number ₹793.95 and DCF intrinsic value ₹424.88; margin of safety is -114.13%.
• PEG of 1.95 implies growth is not cheap, especially with sales growth at just 10.66% and 5-year revenue CAGR at 12.79%.
• Free cash flow of ₹99 Cr is low versus quarterly net profit of ₹166 Cr, suggesting weak cash conversion.
• Dividend yield of only 0.35% provides little income support while waiting for the valuation to normalise.

AI Analysis

Let me look at Caplin Point as an owner, not a speculator. A 70.57% promoter holding tells me the people running it eat their own cooking, and zero debt is exactly the kind of balance sheet I like. Return on equity of 23.30% and ROCE of 25.85% show a business capable of earning more than it costs to fund itself, without using leverage. The Piotroski score of 8/9 and Altman Z of 4.62 reinforce that financial health. Profit growth of 19.09%, against 10.66% sales growth, suggests margins are improving, and quarterly net profit of ₹166 Cr on sales of ₹543 Cr is solid. But I am a buyer only when price gives me an edge, and this price does not. At ₹1,768.05, the stock trades at 21.06 times earnings and 5.10 times book value. The Graham Number is only ₹793.95 and DCF value is ₹424.88. That gives me a margin of safety of minus 114%, meaning I am paying a heavy premium for quality. PEG of 1.95 tells me the current growth rate is already priced in, if not overpaid for. With a dividend yield of just 0.35%, I am not being paid to wait. Free cash flow of ₹99 Cr also troubles me; if annualised net profit is closer to ₹664 Cr, cash conversion is weak, and reported earnings are not being turned into owner earnings. The share is down from ₹2,700, but a falling price is not automatically a bargain. It is only interesting if the fundamentals justify the lower price. Steady, well-run, debt-free pharma businesses are rare, but patience matters more than action. I will keep it on my watch list and wait for either a better price or years of growth to make the valuation reasonable. FairStock's 71/100 'Steady' label seems fair.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer